Cathepsin F Inhibitor Screening Assay Kit
The Cathepsin F Inhibitor Screening Assay Kit is designed to measure the protease activity of Cathepsin F for screening and profiling applications. The Cathepsin F assay kit comes in a convenient 96-well format, with enough purified Cathepsin F (amino acids 20-484), its substrate, and Cathepsin Buffer for 96 reactions.
Figure 1: Illustration of the assay principle.
The substrate is an internally quenched fluorogenic substrate. Proteolysis releases the highly fluorescent substrate from the quencher. Fluorescence intensity increases proportionally to the activity of the protease.
Need us to run inhibitor screens or profile your compounds against Cathepsin F? Check out our Protease Screening Services.
- Adjustable micropipettor and sterile tips
- Fluorescence plate reader capable of measurement at λex360/λem460 nm.
Catalog # | Name | Amount | Storage |
80003 | Cathepsin F, His-Tag* | >1 µg | -80°C |
80350 | Fluorogenic Cathepsin F Substrate (0.5 mM) | 100 µl | -20°C |
4x Cathepsin Buffer | 2 ml | -20°C | |
0.5 M DTT | 200 µl | -20°C | |
79685 | 96-well black microplate | 1 | Room Temp |
* The concentration of protein is lot-specific and will be indicated on the tube containing the protein.
Cathepsin F is a lysosomal cysteine protease that belongs to the papain-like superfamily. It is secreted by macrophages and is thought to play a role in processing and loading peptides into MHC complexes. Cathepsin F is also expressed in atherosclerotic lesions, where it degrades ApoB-100, triggering LDL (low density lipoprotein) aggregation. It has been implicated in tumor invasion and metastasis, and when it is downregulated, it can induce apoptosis of gastric cancer cells. Mutations in cathepsin F have been linked to Alzheimer’s disease and Type B Kuf’s disease. A deeper understanding of the mechanisms of action of cathepsin F, and development of specific inhibitors, may result in new cancer therapy avenues.
Smith K R., et al., 2013. Human Molec. Genetics 22(7): 1417-1423.
Ji C., et al., 2018 Oncol Res 26(1): 83-93.